Expression of energy metabolism related genes in the gastric tissue of obese individuals with non-alcoholic fatty liver disease

Rohini Mehta1,2†, Aybike Birerdinc1,2†, Lei Wang1,2, Zahra Younoszai1,3, Amir Moazzez1,3, Hazem Elariny1,3, Zachary Goodman1,3, Vikas Chandhoke2, Ancha Baranova1,2† and Zobair M Younossi1,3*  

Abstract  
Background: Stomach is an integral part of the energy balance regulating circuit. Studies exploring the effects of cross-system changes in the energy homeostasis in stomach tissue are scarce. The proximity of the stomach to liver - the most common secondary target affected by obesity – suggests that these two organs are exposed to each other’s local secretion. Therefore, we aimed at expression profiling of energy metabolism associated genes in the gastric tissue of obese non-alcoholic fatty liver disease (NAFLD) patients.  
Methods: A total of 24 patients with histologically-proven NAFLD were included. In the gastric tissue, gene expression profiling of 84 energy metabolism associated genes was carried out.  
Results: The accumulation of the fat in the liver parenchyma is accompanied by downregulation of genes encoding for carboxypeptidase E (CPE) and Interleukin 1B (IL1B) in the gastric mucosa of same patient. In patients with high grade hepatic steatosis, Interleukin 1 beta encoding gene with anorexigenic function, IL1B was downregulated. The levels expression of 21 genes, including ADRA2B, CNR1 and LEP were significantly altered in the gastric tissue of NAFLD patients with hepatic inflammation. There were also indications of an increase in the opioid signaling within gastric mucosa that may results in a shift to proinflammatory environment within this organ and contribute to systemic inflammation and the pathogenic processes in hepatic parenchyma.  
Conclusions: We have shown differential expression of energy metabolism associated genes in the gastric tissue of obese NAFLD patients. Importantly, these gene expression profiles are associated with changes in the hepatic parenchyma as reflected in increased scores for hepatic steatosis, inflammation, fibrosis and NASH. This study suggests the complex interplay of multiple organs in the pathogenesis of obesity-related complications such as NAFLD and provides further evidence supporting an important role for gastric tissue in promoting obesity-related complications.

Background  
Energy balance is regulated by a milieu of hormones, cytokines and neurotransmitters. This homeostatic regulation integrates signals from the central nervous system and various peripheral organs and ensures that despite fluctuations in daily food and energy intake, the variation in day to day weight, in most cases, remains negligible [1]. This system-wide crosstalk suggests that the network balancing appetite and satiety is highly complex and, in part, redundant. Stomach is an integral part of this energy balance regulating circuit and is known to relay satiety signals to the hypothalamus [2].  
Interestingly, studies exploring the participation of the stomach in energy homeostasis and the effects of cross-system changes in the energy homeostasis on stomach function are scarce [3-5]. Aside from its obvious role in the digestion and absorption of nutrients, the stomach has endocrine function [3,4]. One of the best examples of the endocrine role of the stomach is seen in its production of the ghrelin, obestatin and leptin, hormones that are known to contribute to many chronic diseases.
associated with obesity [5-7]. Additionally, several recent studies have suggested a role of these molecules in systemic inflammation [8-10]. This indicates the necessity of further studies on the role of gastric tissue in obesity and obesity-related disorders.

Importantly, obesity is associated with changes in gene expression pattern within many types of non-adipose peripheral tissues, including muscle [11], liver [12] and peripheral blood mononuclear cells [13]. Notably, the effect of obesity on the stomach tissue and the role of the stomach in metabolic dysfunction has been largely overlooked. Histological studies of the stomach tissue in obese patients reported a number of visible changes within the mucosa in a majority of samples [14,15]. It is very difficult to say if these changes are sequelae of systemic inflammation or active contributors to weight gain. It is possible that altered secretory patterns associated with gastric inflammation augment the development of obesity-associated conditions. The proximity of the stomach to liver - the most common secondary target affected by obesity - suggests that these two organs are exposed to each other’s local secretion. Thereby, the gene expression responses of these organs in responder to central adiposity can be potentially inter-related.

An important complication of obesity, non-alcoholic fatty liver disease (NAFLD), is estimated to affect ~30% of the US adults [16]. The progressive form of NAFLD or non-alcoholic steatohepatitis (NASH) is characterized by the accumulation of fat in the liver along with ballooning of hepatocytes, lobular inflammation with or without fibrotic changes in hepatic parenchyma. It is important to note that deposition of the fat in the liver is associated with impaired sensitivity to insulin [17,18]. Various adipokines and hormones produced by visceral adipose tissue, gastric tissue and liver tissue can potentially contribute to the development of NAFLD and its progression to NASH [10,12].

In a previous study, we demonstrated an altered pattern of gene expression for cytokine and chemokine encoding genes in the gastric tissue of obese individuals with NAFLD [19]. In this study, we further explore this relationship by gene expression profiling of energy metabolism associated genes in the gastric tissue of obese NAFLD patients.

Methods

Samples

Stomach tissue samples were collected after informed consent from morbidly obese NAFLD patients during laparoscopic sleeve gastrectomy. The tissue was snap frozen in liquid nitrogen and stored at −80°C. A liver biopsy was performed at the same time; all biopsies were read by same hepatopathologist. Clinical and laboratory variables from the time of surgery were extracted from medical records (Table 1). Other causes of chronic liver disease were excluded based on negative serology for hepatitis B and C, no reported history of toxic exposure and excessive alcohol consumption (> 10 gram/day in women and >20 gram/day in men) was also considered as an exclusion criteria. No patients were receiving thiazolidinediones (TZDs), proton pump inhibitors or other medications for gastritis as well as those associated with fatty liver. The study was approved by Internal Review Board of Inova Hospital (Federal Assurance FWAA00000573).

All liver biopsies were read by same hepatopathologist. Histological features such as portal inflammation, lymphoplasmacytoid lobular inflammation, polymorphonuclear lobular inflammation, Kupffer cell hypertrophy, apoptotic bodies, focal parenchymal necrosis, glycogen nuclei, hepatocellular ballooning, and Mallory-Denk bodies were evaluated in the H & E sections. The extent of steatosis was graded based on an estimate of the percentage of tissue occupied by fat vacuoles as follows: 0 = none, 1 = <5%, 2 = 6-33%, 3 = 34-66%, 4 = >66%. NASH was defined as steatosis, lobular inflammation, and ballooning degeneration with or without Mallory Denk bodies, and with or without fibrosis. The extent of various immune cell infiltration such as lymphoplasmacytoid cells, polymorphonuclear cells and Kupffer cell hypertrophy was assessed by hematoxylin-eosin (H&E) staining. For each category, scores were assigned based on the following system: 0 = none, 1 = few, 2 = moderate, 3 = many. The extent of

| Table 1 Clinical and demographic data of the patient cohorts profiled for expression of obesity-related genes |
|---------------------------------------------------------------|
| **Demographic or clinical parameter** | **Mean ± SD, or %** |
| **(N = 24)** | | |
| BMI (*) | 47.96 ± 8.2 |
| AST, (U/L) (*) | 24.92 ± 8.37 |
| ALT, (U/L) (*) | 30.38 ± 12.88 |
| Total cholesterol, mg/dL (*) | 205.08 ± 41.82 |
| HDL, mg/dL (*) Females | 50.33 ± 11.85 |
| HDL, mg/dL (*) Males | 39.66 ± 41.82 |
| Triglyceride, mg/dL (*) | 197 ± 105.39 |
| Age | 43.93 ± 10.2 |
| Gender (Females) | 79% (N = 19) |
| Race (caucasian) | 67% (N = 16) |
| Advanced inflammation (score ≥ 3) | 54% (N = 13) |
| NASH | 63% (N = 15) |
| Advanced steatosis | 42% (N = 10) |
| Fibrosis | 79% (N = 19) |
| Steatosis with presence of hepatic inflammation | 96% (N = 23) |
| NASH with presence of hepatic inflammation | 62.5% (N = 15) |

Values marked by asterisk (*) are given as Mean ± SD. SD: standard deviation; BMI: Body Mass Index; NASH: Non-Alcoholic Steatohepatitis; AST: aspartate aminotransferase; ALT: Alanine transaminase; HDL: High-density lipoprotein.
hepatic inflammation was determined based on the sum of the above individual scores with a score of ≥ 3 being considered as advanced hepatic inflammation and score of <3 being considered as mild/no hepatic inflammation. Severity of pericellular and portal fibrosis was determined by Masson trichrome staining of the biopsy, respectively. The scoring was as follows: 0 = no fibrosis, 1 = mild fibrosis, 2 = moderate fibrosis, 3 = marked fibrosis. Severity of total hepatic fibrosis was determined based on sum of the individual scores (pericellular and portal fibrosis) with score of ≥ 3 being considered as advanced hepatic fibrosis and score of <3 being considered as mild/no hepatic fibrosis. Patients with hepatic steatosis or NASH were considered to have NAFLD.

RNA extraction and reverse transcription
Total cellular RNAs were extracted from fundic stomach tissue samples (N = 24) using RNeasy kit (Qiagen, USA) according to manufacturer’s instructions. Concentration and quality of the extracted RNAs were measured using absorbance at 260 nm (A260) and 280 nm (A280) with GeneQuant1300 spectrophotometer (GE Healthcare, USA). Only mRNA samples with A260/A280 Ratio in range of 1.8 - 2.1 were utilized. Additionally, integrity of each total RNA was evaluated by 1% agarose gel electrophoresis with ethidium bromide. Extracted total RNAs were reverse transcribed to single strand cDNA using RT2 first strand kit (Qiagen, USA), per manufacturer’s protocol.

Quantitative real time PCR analysis
Gene expression profiling experiments were performed on cDNA samples using RT² Profiler PCR Arrays (Qiagen, USA) that include 84 orexigenic, anorexigenic, and energy expenditure related genes and their receptors along with five housekeeping genes, according to the manufacturer’s protocol (Additional file 1: Table S1). Quantitative real-time PCR reactions were performed in 96 well PCR format using Bio-Rad CFX96 Real Time System (BioRad Laboratories, USA) with a ramp speed of 1°C/sec. The Real Time PCR mixtures consisted of 1 μL cDNA, 7.5 μL of RT PCR Master mix (Qiagen, USA) in a final volume of 25 μL. The thermal profile of the RT-PCR procedure was repeated for 50 cycles: 1) 95°C for 10 min; 2) 10 s denaturation at 95°C, 15 s annealing at 60°C (amplification data collected at the end of each amplification step); 3) dissociation curve consisting of 10 s incubation at 95°C, 5 s incubation at 65°C, a ramp up to 95°C (Bio-Rad CFX96 Real Time System, USA). Melt curves were used to validate product specificity.

Analysis of gene expression profiles
The threshold cycle (Ct) values were obtained for each gene; only Ct values less than 40 were considered for analysis. Ct values of control wells (genomic DNA control, reverse transcriptase control, positive PCR control) were examined separately and used for determining the quality of the run, according to manufacturer’s recommendations. The average of five housekeeping genes: B2M, HPRT1, RPL13A, GAPD, and ACTB, was used to normalize the Ct values. Relative expression was determined using the delta delta Ct method (1). Fold change (2) for each gene was calculated as follows:

\[ \Delta \Delta C_t = 2^{-\Delta C_t} \]  
\[ \text{Fold Change} = \frac{\Delta C_t^{\text{Expt}}}{\Delta C_t^{\text{Control}}}. \]

Statistical analysis
The study was designed to detect changes in gene expression in the stomach of patients with advanced forms of NAFLD as compared to those with milder forms. The scorings for each histopathological state were as described above. Following comparisons were performed:

1. Severe disease state as compared to mild/no disease state or
2. Presence of the disease as compared to no disease

The significance of differences in gene expression between the groups was assessed using univariate non-parametric Mann–Whitney tests. Spearman’s coefficients of correlation were used to determine whether two variables co-vary, and to measure the strength of their relationship. The independent effects of significant variables (\(P < 0.05\)) on advanced inflammation, NASH and steatosis were assessed using multiple stepwise regression analysis, with both the backward and forward stepwise selection procedures.

Results
A total of 24 patients with histologically-proven NAFLD were included. Clinical and demographic data for patients are summarized in Table 1. In the gastric tissue, gene expression profiling of 84 energy metabolism associated genes (Additional file 1: Table S1) was carried out.

Gene expression signature associated with advanced hepatic steatosis
When mRNA expression levels were compared in samples of patients with advanced steatosis (Grade ≥ 3) to that with mild or no steatosis (Grade < 3), significant decreases in expression levels of mRNAs encoding CPE (−1.88, \(p < 0.04\)) and IL1B (−2.5, \(p < 0.05\)) genes were observed (Table 2).
Gastric gene expression signature associated with NASH

mRNAs encoded by IL1R1 (1.99, p < 0.04), OPRM1 (2.65, p < 0.02), SIGMAR1 (3.13, p < 0.03), THRBR (1.94, p < 0.02) and ZFP91 (3.09, p < 0.01) genes were upregulated in gastric samples of patients with NASH as compared to those without NASH (Table 2).

Gene expression signature associated with advanced hepatic inflammation

When samples collected from patients with advanced hepatic inflammation (score ≥ 3) were compared to that of patients with mild inflammation, 21 genes (0.001 < p < 0.05) were found to have increased gene expression (fold change range: 2.1 – 6.9) (Table 2). Among these genes, expression levels of ADRA2B, CNR1 and LEP were also found to be correlated (r > 0.5, p < 0.05) with the degree of hepatic inflammation (Table 3). Additionally, expression levels of IL1A and OPRM1 were also correlated with the degree of hepatic inflammation (r > 0.5, p < 0.05) (Table 3).

Gene expression signature associated with hepatic fibrosis

Comparison of gastric samples collected from patients with fibrosis and samples from those without fibrosis showed the mRNAs for NTS and OPRK1 genes were more than 5-fold upregulated in presence of fibrosis (p < 0.02) (Table 2). Analysis of correlations showed that mRNA levels for GHR and IL1A genes consistently increase along with a progression of fibrosis (r > 0.5, p < 0.05) (Table 3).

Association of gene expression with risk factors for NAFLD

The levels of mRNA expression for CPE were correlated positively to BMI, while mRNA expression levels for ZFP91 and BMI were correlated negatively (P < 0.01) (Table 3). Furthermore, fasting glucose levels were positively correlated with expression levels of mRNAs encoded by AGRP, NMB, THRBR, TFF and UCPI genes Serum triglyceride levels was positively correlated with expression levels of 14 genes (Table 3), including ADIPOQ and APOA4 and negatively correlated with that of CPD (Table 3).

Discussion

Obesity is commonly viewed as an accumulation of excessive number of enlarged adipocytes within an abdominal cavity and in subcutaneous depots. In addition, obesity is also associated with fat accumulation in a number of organs, in particular, muscle and liver [20]. These ectopic sites are not well adapted for fat storage and even modest increases in lipid concentrations can be manifested as tissue dysfunction due to lipotoxicity [21]. A spectrum of lipotoxicity-associated changes in expression patterns has been demonstrated both in muscle and liver of obese patients [22-24] as well as in the animal models of obesity [25].

In addition to fatty infiltration of these organs, a number of other changes can happen in obese patients. For

### Table 2 List of obesity related genes significantly upregulated in gastric tissues of patients with the following pathological conditions

| Genes                  | Fold regulation | P value |
|------------------------|-----------------|---------|
| Advanced steatosis (grade ≥ 3) vs mild/no steatosis (score < 3) |
| CPE                    | −1.8            | 0.04    |
| IL1B                   | −2.5            | 0.05    |
| NASH present vs No NASH |
| IL1R1                  | 1.99            | 0.04    |
| OPRM1                  | 2.65            | 0.02    |
| SIGMAR1                | 3.13            | 0.03    |
| THRBR                  | 1.94            | 0.02    |
| ZFP91                  | 3.09            | 0.01    |
| Advanced hepatic inflammation (score ≥ 3) vs mild/no hepatic inflammation (score < 3) |
| ADCYAP1                | 5.5             | 0.04    |
| ADRA2B                 | 2.1             | 0.02    |
| BDNF                   | 3.5             | 0.03    |
| CNR1                   | 5.1             | 0.001   |
| CNTR2                  | 3.2             | 0.02    |
| GALR1                  | 2.5             | 0.04    |
| GH2                    | 5.1             | 0.01    |
| GRGR                   | 4.1             | 0.004   |
| IAPP                   | 2.5             | 0.03    |
| LEP                    | 2.3             | 0.04    |
| LEPR                   | 2.3             | 0.02    |
| MC3R                   | 4.1             | 0.02    |
| NMB                    | 2.4             | 0.04    |
| NMU                    | 3.9             | 0.004   |
| NMUR1                  | 6.9             | 0.03    |
| PPARGC1A               | 4.1             | 0.006   |
| PRIHR                  | 4.2             | 0.02    |
| RAMP3                  | 2.5             | 0.02    |
| SIGMAR1                | 2.3             | 0.01    |
| SSTR2                  | 3.2             | 0.04    |
| UCN                    | 4.9             | 0.04    |
| Fibrosis present vs no fibrosis |
| NTS                    | 6.7             | 0.02    |
| OPRK1                  | 5.6             | 0.01    |
| Gastritis present vs no gastritis |
| C3                     | −2.1            | 0.04    |
| DRO1                   | 2.6             | 0.02    |

Advanced Liver Inflammation (score ≥ 3) (N = 13), Advanced Steatosis (score ≥ 3) (N = 10), NASH# (N = 15), Fibrosis# (N = 19), Gastritis# (N = 11). #Comparison was performed to groups of patients without the condition listed.

Gastric gene expression signature associated with NASH

mRNAs encoded by IL1R1 (1.99, p < 0.04), OPRM1 (2.65, p < 0.02), SIGMAR1 (3.13, p < 0.03), THRBR (1.94, p < 0.02) and ZFP91 (3.09, p < 0.01) genes were upregulated in gastric samples of patients with NASH as compared to those without NASH (Table 2).
instance, the gastric tissue of obese individuals undergoes changes that are visible by histologic assessment. In fact, oxyntic mucosa of morbidly obese patients without metabolic syndrome contains more ghrelin-immunoreactive cells as compared to that of non-obese subjects [26]. Furthermore, serum levels of three protein products of ghrelin gene (acylated ghrelin, des-acylated ghrelin, and obestatin) have been shown to be elevated in obese patients with NAFLD [10,27]. Finally, in a previous study, we have shown that mRNAs encoding for various soluble molecules are overproduced in the gastric tissue of morbidly obese patients with advanced forms of NAFLD.

In this study, we assessed the gene expression patterns for energy metabolism-related genes in the gastric tissue of morbidly obese patients with NAFLD. In particular, we observed that accumulation of the fat in the liver parenchyma is accompanied by downregulation of genes encoding for carboxypeptidase E (CPE) and Interleukin 1B (IL1B) in the gastric mucosa of same patient. Given the proximity and intimate interaction of stomach with liver, we believe these observations in the gastric tissue may have important implications for changes seen in the hepatic tissue.

Carboxypeptidase E is involved in the post-translational processing of many prohormones and neuropeptides, including those expressed predominantly in gastrointestinal tract and playing a central role in energy homeostasis [28]. In models animals, inactivating of both CPE alleles result in obesity that is caused by defective nutrient partitioning rather than by increased food consumption [28]. Not much is known about an expression of CPE in humans, however, there are indications that allelic variations in this gene may contribute to coronary atherosclerosis, another complication of obesity and metabolic syndrome [29]. To date, ours is the first report to link the decrease in human non-adipose peripheral tissue expression of CPE to obesity related condition.

Another mRNA downregulated in gastric tissue of patients with high grade hepatic steatosis encodes for Interleukin 1 beta (IL1B), an inflammatory cytokine with anorexigenic function [30,31]. IL1β inhibits gene expression of orexigenic ghrelin [32] and suppresses the production of gastric acid and gastrin [32]. However, it was shown recently that IL1β supports ectopic fat accumulation in hepatocytes and adipose-tissue macrophages [33]. Interestingly, high-fat-fed (HFF) mice exhibited a preferential increase of IL-1β concentration in portal compared to systemic blood [34], thus, indicating that the liver may differ in its IL-1β regulation from other perihepatic tissues.

It important to note that obesity is known to be associated with low grade systemic inflammation. Furthermore inflammation plays an important role in the pathogenesis of progressive NAFLD or NASH. In our

### Table 3 Analysis of correlations between expression levels of various genes and scored characteristics of NAFLD

| Gene       | Correlation (r) | p value |
|------------|----------------|---------|
| **NASH**   |                |         |
| IL1R1      | 0.42           | 0.03    |
| OPRM1      | 0.43           | 0.034   |
| SIGMAR1    | 0.51           | 0.009   |
| THRB       | 0.40           | 0.05    |
| ZFP91      | 0.43           | 0.03    |
| **Degree of inflammation** |               |         |
| ADRA2B     | 0.45           | 0.02    |
| CNR1       | 0.43           | 0.03    |
| LEP        | 0.40           | 0.04    |
| IL1A       | 0.43           | 0.03    |
| OPRM1      | 0.42           | 0.03    |
| **Fibrosis** |               |         |
| GHR        | 0.42           | 0.03    |
| IL1A       | 0.48           | 0.01    |
| **BMI**    |                |         |
| CPE        | 0.47           | 0.01    |
| ZFP91      | –0.48          | 0.01    |
| **Fasting glucose (mg/dL)** |     |         |
| AGRP       | 0.52           | 0.008   |
| NMB        | 0.41           | 0.04    |
| THRB       | 0.55           | 0.005   |
| TNF        | 0.42           | 0.04    |
| UCP1       | 0.65           | 0.0005  |
| **Serum triglycerides (mg/dL)** |               |         |
| ADCYAP1R1  | 0.48           | 0.01    |
| ADIPOQ     | 0.50           | 0.01    |
| APOA4      | 0.44           | 0.02    |
| CNTFR      | 0.41           | 0.04    |
| CALCA      | 0.44           | 0.02    |
| DRO2       | 0.49           | 0.01    |
| GCCR       | 0.43           | 0.03    |
| GH2        | 0.41           | 0.04    |
| GLP1R      | 0.56           | 0.003   |
| IL6        | 0.42           | 0.03    |
| NMUR1      | 0.48           | 0.01    |
| INTRK2     | 0.40           | 0.04    |
| PPARC1A    | 0.42           | 0.04    |
| PRKLR      | 0.43           | 0.03    |
| CPD        | –0.42          | 0.03    |
study, the levels of 21 genes were significantly altered in the gastric tissue of NAFLD patients with hepatic inflammation (Table 2). Amongst these, \textit{ADRA2B}, \textit{CNR1}, \textit{LEP} also significantly correlated \((r = 0.5, p < 0.05)\) with the degree of hepatic inflammation.

Another interesting finding of our study relates to expression of leptin in the gastric tissue. The secretion of the leptin is acutely increased in response to inflammation and inflammatory cytokines such as TNF-\(\alpha\) and IL-1\(\beta\). Although, the major site of leptin production is white adipose tissue, the leptin gene expression has also been detected in the gastric epithelium and in the glands of the gastric fundic mucosa in both rats \([35]\), and humans \([36]\). There is a body of evidence implicating the leptin in the pathogenesis of NAFLD. In a study by Chitturi et al., the leptin levels in patients with biopsy proven NASH were twice those found in non-NASH matched controls \([37]\). Our measurement of \textit{LEP} mRNA in the gastric tissue of patients with various stages of NAFLD showed similar trends. \textit{LEP} was upregulated in the gastric tissue of patients with advanced hepatic inflammation and positively correlated with the inflammation scores of patients with NAFLD (Table 3). It is important to note that the leptin also functions as an anorexigenic hormone as it suppresses appetite \([38]\). Thus, an increase in its production within gastric mucosa may be a compensatory response to metabolic shift of obesity. Alternatively, observed increase in \textit{LEP} expression may serve as an indicator of leptin tolerance or leptin resistance which is commonly reported in obese individuals \([39]\).

It is also interesting to note that the leptin has also been shown to stimulate gene expression of neurotensin (\textit{NTS}), a neuropeptide that is known for its expression in the small intestine \([40]\) and for its involvement in food intake and glucose homeostasis in the peripheral tissues \([41]\). Furthermore, receptors to neurotensin are present at the membranes of hepatocytes. It is postulated that neurotensin protects stressed liver parenchyma as evident from reduced ALT levels and hepatic oxidative stress and increase in hepatocyte proliferation in NTS-treated cholestatic model animals \([42]\).
study an increase in expression of NTS was also seen in stomach samples of subjects with liver fibrosis as compared to those with no/mild fibrosis (Table 2). It is thus, plausible that gastric neurotensin enters the liver via the portal vein and alleviates liver fibrosis. It is also possible that gastric-produced neurotensin may, at least in part, counteract pro-fibrotic action of its inducer, the leptin in the hepatic parenchyma.

Another important gene with expression of our NAFLD patients with significant inflammation is CNR1/ CB1. Endocannabinoid receptor CNR1 is known for its expression throughout the gastrointestinal tract [43]. CNR1 is implicated in de novo fatty acid and cholesterol biosynthesis, in both the liver and the adipose tissue [44]. In mouse models, an activation of this receptor in the liver increases de novo synthesis of fatty acids [45]. Furthermore, CNR1 antagonists improve metabolic parameters by exerting an anorexigenic effect, suppressing lipogenesis and reducing inflammation [44]. Peripheral CNR1 blockade has also been shown to reverse leptin resistance commonly seen in obese patients. This reversal is mediated by a decrease in leptin secretion through adipose tissue [46]. Thus, the concomitant increase in expression of gastric CNR1 and LEP in patients with hepatic inflammation seen in this study may be another indication of contribution of peripheral leptin resistance to obesity-associated NASH. On the other hand, CNR1 was recently implicated in the pathophysiology of acute and chronic liver conditions, including inflammation, fibrogenesis and steatosis [47]. While faintly expressed in normal livers, CNR1 undergo substantial up-regulation after liver injury induced by various causes [48]. It is tempting to speculate that observed increase in expression of gastric CNR1 in morbidly obese patients with advanced hepatic inflammation may point to a similar regulatory process within the stomach and the liver under conditions of positive energy balance.

Another interesting finding of our study is related to an increase in the gene expression of opioid receptors OPRM1 and OPRK1 (Figure 1). Involvement of opioid receptors in the development of obesity has been widely recognized. This is potentially due to well-documented anorexigenic effects of administering general opioid receptor antagonists [49]. Interestingly, recent studies have also implicated opioid receptors in inflammation. In fact, polymorphism in the human mu-opioid receptor OPRM1 gene was associated with baseline proinflammatory cytokine levels in healthy subjects [50]. We have previously shown an altered inflammatory cytokine profiles in the gastric tissue of morbibly obese patients with NAFLD [19]. It is possible that an increase in the opioid signaling within gastric mucosa results in a shift to proinflammatory environment within this organ. In turn, an increase in the gastric production of proinflammatory cytokines may contribute to systemic inflammation and augment inflammatory processes in hepatic parenchyma (Figure 1).

Conclusions
In conclusion, we have shown differential expression of energy metabolism associated genes in the gastric tissue of obese NAFLD patients. Importantly, these gene expression profiles are associated with changes in the hepatic parenchyma as reflected in increased scores for hepatic steatosis, inflammation, fibrosis and NASH (Figure 2). Importantly, we see that the gene expression changes in stomach are distinct and non-overlapping in different stages of NAFLD. This study suggests the complex interplay of multiple organs in the pathogenesis of obesity-related complications such as NAFLD and provides further evidence supporting an important role for gastric tissue in promoting obesity-related complications.
7. Fujimiya M, Ataka K, Asakawa A, Chen CV, Kato I, Inui A: Regulation of gastrointestinal motility: acyl ghrelin, des-acyl ghrelin and obestatin and hypothalamic peptides. Digestion 2012, 85:90–94.

8. Fernández-Riegos P, Najib S, Santos-Alvarez J, Martín-Romero C, Pérez-Pérez A, González-Yanes C, Sánchez-Margaréte V: Role of leptin in the activation of immune cells. Mediators Inflamm 2010, 2010:658349.

9. Baatar D, Patel K, Taub DD: Effects of ghrelin on inflammation and the immune system. Mol Cell Endocrinol 2011, 340:44–58.

10. Stepet M, Aabvi M, Jarrar M, Wang L, Stepanova V, Elariny H, Aybek H: Association of obestatin, ghrelin, and inflammatory cytokines in obese patients with non-alcoholic fatty liver disease. Obes Surg 2011, 21:1750–1757.

11. Wilgjaardaen MA, van der Zon GC, van Dijk KW, Pijl H, Guigas B: Effects of prolonged fasting on AMPK signaling, gene expression, and mitochondrial respiratory chain content in skeletal muscle from lean and obese individuals. J Cell Biol 2013, 204:1012–1021.

12. Baranova A, Schlachta K, Elariny H, Jarrar M, Bennett C, Nugent C, Gowdy SJ, Younoszai Z, Collantes R, Chandhoke V, Younossi ZM: Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease. Obes Surg 2007, 17:1111–1118.

13. Yamaoka M, Maeda N, Nakamura S, Kashine S, Nakagawa Y, Higue-Shimizu A, Okita K, Imagawa A, Matsuzawa Y, Matsubara K, Funahashi T, Shitomura I: A pilot investigation of visceral fat adiposity and gene expression profile in peripheral blood cells. PLoS One 2012, 7:94777.

14. Vrabie CD, Cojocaru M, Waller M, Sindelaru R, Copaescu C: The histopathological effects of ghrelin in obese patients who underwent sleeve gastrectomy. Dicke Med J 2010, 7:397–103.

15. Gündoğan M, Çali Demirkan N, Tekin K, Aybek H: Gastric histopathological findings and ghrelin expression in morbid obesity. Turk Patoloji Derg 2013, 29:19–26.

16. Vernon G, Baranova A, Younoszi ZM: Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34:274–285.

17. Ryousy L, Håkkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Järvinen H: Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000, 49:749–758.

18. Seppele-Lindoos A, Vehkavaara S, Håkkinen AM, Goto T, Westerbacka J, Sovijärvi A, Halavaara J, Yki-Järvinen H: Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002, 87:3023–3028.

19. Mehta R, Birerdinc A, Neupane A, Shamsaddini A, Afendy A, Elariny H, Shelef I, Carmi Y, Voronov E, Apte RN, Lewis E, Haim Y, Konrad D, Bashan N, Rudich A: Interleukin-1β regulates fat-liver crosstalk in obesity by auto-paracrine modulation of adipose tissue inflammation and expandability. PLoS One 2013, 8:e53626.

20. Bado A, Levasseur S, Attoub S, Kermorgant S, Lainejou JP, Bortoluzzi MN, Moizo L, Lehy T, Guerre-Millo M, Le Marchand-Brustel Y, Lewin MJ: The stomach is a source of leptin. Nature 1998, 394:790–793.

21. Sobhani I, Bado A, Missavage C, Buze S, Kermorgant S, Lainejou JP, Attoub S, Lehy T, Henin D, Mignon L, Lewin MJ: Leptin secretion and leptin receptor in the human stomach. Gut 2000, 47:178–183.

22. Chitturi S, Farell G, Frost L, Krikets A, Lin R, Fung C, Liddle C, Samarasinghe D, George J: Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002, 36:403–409.

23. Yang R, Barouch LA: Leptin signaling and obesity: cardiovascular consequences. Circ Res 2007, 101:545–559.

24. Blüher S, Mantzoros CS: Leptin in humans: lessons from translational research. Am J Clin Nutr 2009, 89:9915–9975.

25. Egerod KL, Engelstoft MS, Grunddal KV, Nahr MK, Secher A, Sakota I, Pedersen J, Windlev JA, Fuchtbauer EM, Olesen J, Sundler F, Christensen JP, Wretup N, Olesen AM, Holst JJ, Zignan JM, Poulsen SS, Schwartz TM: A major line of enteroenodocrine cells express CK1, secretion, GP, GLP-1, PYY, and neurotensin but not somatostatin. Endocrinology 2012, 153:5782–5795.

26. Mazella J, Béaudeau-Dufour S, Devader C, Massa F, Coppola T: Neurotensin and its receptors in the control of glucose homeostasis. Front Endocrinol (Lausanne) 2012, 3:143.

27. Gutierrez-Grobe Y, Villalobos-Blaquez I, Sánchez-Lara K, Villa AR, Ponciano-Rodriguez G, Ramos MH, Chavez-Tapia NC, Uribe M, Méndez-Sánchez N: High ghrelin and obesity levels and low risk of developing fatty liver. Ann Hepatol 2010, 9:52–57.

28. Cavley NW, Wetsel WC, Murthy SR, Park JJ, Pakac K, Loh YP: New roles of carboxypeptidase E in endocrine and neural function and cancer. Endocr Rev 2013, 34:216–253.

29. Jia EZ, Wang J, Yang ZJ, Zhu TB, Wang LS, Wang H, Li CJ, Chen B, Cao KJ, Huang J, Ma WZ: Association of the mutation for the human carboxypeptidase E gene exon 4 with the severity of coronary artery atherosclerosis. Mol Biol Rep 2009, 36:245–254.

30. Neyts TM, Sawchenko PE: Involvement of the arcuate nucleus of the hypothalamus in interleukin-1-induced anorexia. J Neurosci 2002, 22:5091–5099.

31. Kornman KS: Interleukin 1 genetics, inflammatory mechanisms, and nutrigenetic opportunities to modulate diseases of aging. Am J Clin Nutr 2006, 83:475S–483S.

32. Asamakopoulos SF, Tsamandas AC, Georgiou CD, Vagianos CE, Scopas CA: Bombesin and neurotensin exert antiproliferative effects on oval cells and augment the regenerative response of the cholestatic rat liver. Peptides 2010, 31:2294–2309.

33. Pacher P, Batkai S, Kunos G: The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006, 58:389–462.

34. Zhao W, Fong O, Muise ES, Thompson JR, Weingarth D, Qian S, Fong TM: Genome-wide expression profiling revealed peripheral effects of cannabinoid receptor 1 inverse agonists in improving insulin sensitivity and metabolic parameters. Mol Pharmacol 2010, 78:350–359.

35. Pagano C, Pilon C, Calcagno A, Urbanet R, Rossato M, Milan G, Bianchi K, Mukhopadhyay B, Chedester L, Liow JS, Innis RB, Cheng K, Rice KC, Deschamps JR, Chovrat RJ, McElroy JF, Kunos G: Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab 2012, 16:167–179.
47. Aller R, de Luis DA, Pacheco D, Velasco MC, Conde R, Izaola O, González Sagrado M: Influence of G1359A polymorphism of the cannabinoid receptor gene (CNR1) on insulin resistance and adipokines in patients with non alcoholic fatty liver disease. *Nutr Hosp* 2012, 27:1637–1642.

48. Izzo AA, Camilleri M: Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. *Gut* 2008, 57:1140–1155.

49. Czyżyk TA, Romero-Picó A, Pintar J, McKinzie JH, Tschöp MH, Statnick MA, Nogueiras R: Mice lacking δ-opioid receptors resist the development of diet-induced obesity. *FASEB J* 2012, 26:3483–3492.

50. Matsunaga M, Isowa T, Murakami H, Kasugai K, Yoneda M, Kaneko H, Ohira H: Association of polymorphism in the human mu-opioid receptor OPRM1 gene with proinflammatory cytokine levels and health perception. *Brain Behav Immun* 2009, 23:931–935.

doi:10.1186/1471-230X-14-72

Cite this article as: Mehta et al.: Expression of energy metabolism related genes in the gastric tissue of obese individuals with non-alcoholic fatty liver disease. *BMC Gastroenterology* 2014 14:72.